05:17 PM EST, 03/06/2025 (MT Newswires) -- Oruka Therapeutics ( ORKA ) reported a Q4 net loss late Thursday of $0.49 per diluted share.

Analysts polled by FactSet expected a loss of $0.74.

Oruka did not provide revenue for the quarter and year-ago figures.

The company said its cash, cash equivalents and marketable securities at the end of 2024 were $394 million and are projected to fund the company through 2027.